<DOC>
	<DOCNO>NCT01550055</DOCNO>
	<brief_summary>The primary purpose study evaluate clinical response safety cetuximab plus irinotecan synchronously/subsequently patient KRAS wild-type metastatic colorectal cancer</brief_summary>
	<brief_title>Study Cetuximab Treat KRAS Wild Type Metastatic Colorectal Cancer</brief_title>
	<detailed_description>CMAB009 recombinant , human/mouse chimeric monoclonal antibody ( mAb ) bind specifically extracellular domain EGFR . It compose Fv region murine anti-EGFR antibody human IgG1 heavy k light chain constant region express Chinese hamster ovary cell . It biosimilar cetuximab ( C225 , Erbitux® ) develop Shanghai Zhangjiang Biotechnology Limited Company produce Biomabs . Phase I study result suggest CMAB009 show well-tolerated safety profile primary efficacy . This multicenter , open-label study determine whether add cetuximab ( CMAB009 ) irinotecan increase response rate prolongs survival patient KRAS wild-type metastatic colorectal cancer ( mCRC ) previously treat fluoropyrimidine oxaliplatin .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>histologically confirm metastatic colorectal adenocarcinoma KRAS wildtype tumor , EGFRexpressing EGFRnonexpressing immunohistochemistry ; measurable lesion , least 1cm diametre CT MRI , least 2cm diametre physical examination iconography ECOG performance status 0 1 Failure ( disease progression/discontinuation due toxicity ) fluoropyrimidine oxaliplatin treatment , stop least one month thereafter , irinotecannaïve Previous irinotecan antiEGFR therapy hematologic function : hemoglobin , less 90g per liter ; neutrophil count , less 1500 per cubic millimeter ; platelet count , less 100,000 per cubic millimeter liver function : bilirubin , 1.0 time upper limit normal ; aspartate aminotransferase alanine aminotransferase , 5.0 time 2.5 time upper limit normal hepatic metastasis Renal function : serum creatinine , 1.5 time upper limit normal Patients symptomatic central nervous system metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>KRAS wild-type</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>CMAB009 Plus Irinotecan</keyword>
	<keyword>Phase II/III</keyword>
</DOC>